Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Paxman

57.00 SEK

+1.79 %

Less than 1K followers

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+1.79 %
-13.90 %
-26.92 %
-31.82 %
-13.11 %
-22.97 %
+26.67 %
+148.91 %
+422.94 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Read more
Market cap
1.33B SEK
Turnover
6.13M SEK
Revenue
253.01M
EBIT %
13.24 %
P/E
27.01
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27/2
2026

Annual report '25

21/5
2026

Interim report Q1'26

22/5
2026

General meeting '26

All
Press releases
ShowingAll content types
Press release11/27/2025, 4:59 PM

DNB Carnegie Access: Paxman: Key highlights from Capital Markets Day

Paxman
Press release11/24/2025, 6:45 PM

Rättelse: Ytterligare uppdaterade uppgifter om ersättning för OPPS

Paxman
Press release11/24/2025, 6:45 PM

Correction: Further updated Information on OPPS Reimbursement

Paxman

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/24/2025, 5:41 PM

Rättelse: Uppdaterade uppgifter om ersättning för OPPS

Paxman
Press release11/24/2025, 5:41 PM

Correction: Updated Information on OPPS Reimbursement

Paxman
Press release11/24/2025, 5:00 PM

DNB Carnegie Access: Paxman: CMS Final Rule landed neutral – long-term story intact

Paxman
Press release11/24/2025, 3:45 PM

Paxman meddelar att CMS har fastställt de slutliga Medicare-ersättningarna för 2026 för mekanisk skalpkylning inom sjukhusens öppenvård och ersättningssystemet för läkare.

Paxman
Press release11/24/2025, 3:45 PM

Paxman announces that CMS has finalized the 2026 Medicare payment rates for mechanical scalp cooling under the Hospital Outpatient and Physician Fee Schedule.

Paxman
Press release11/17/2025, 1:22 PM

DNB Carnegie Access: Paxman: Margin pressure as expected, outlook still good – Q3 review

Paxman
Press release11/17/2025, 8:28 AM

Redeye: Paxman Q3 (Review) - Softer sales than expected, but outlook remains strong

Paxman
Press release11/14/2025, 7:03 AM

DNB Carnegie Access: Paxman: Meets our expectations on profitability – Q3 initial comment

Paxman
Regulatory press release11/14/2025, 6:00 AM

PAXMAN publishes its interim report for Q3 2025

Paxman
Regulatory press release11/14/2025, 6:00 AM

PAXMAN publishes the interim report for Q3 2025

Paxman
Press release11/7/2025, 10:15 AM

Inbjudan: Livesänd presentation med Richard Paxman – Q3 2025

Paxman
Press release11/7/2025, 10:15 AM

Invitation: Live Presentation with CEO Richard Paxman – Q3 2025

Paxman
Press release10/24/2025, 8:00 AM

Reminder- PAXMAN invitation to Capital Market Day

Paxman
Press release10/20/2025, 3:42 PM

DNB Carnegie Access: Paxman: First full quarter post-Dignitana deal – Q3 preview

Paxman
Press release10/20/2025, 12:01 PM

Paxman tillkännager framsteg i sin kliniska prövning av cellgiftsinducerad perifer neuropati, med de senaste data presenterade vid EONS18-konferensen som en del av ESMO®-kongressen 2025

Paxman
Press release10/20/2025, 12:01 PM

Paxman announces progress of its Clinical Trial for Chemotherapy Induced Peripheral Neuropathy, with latest data presented at EONS18 Conference part of ESMO® Congress 2025

Paxman
Press release10/17/2025, 1:50 PM

PAXMAN meddelar att Paxman Limb Cryocompression System (PLCS) har godkänts av FDA:s Safer Technologies Program (STeP).

Paxman
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.